Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 1999

View Archived Issues

Advances at Ligand during and following close of third quarter

Avant granted U.S. patent for use of TP-20 in stroke

Combination therapy containing GTI-2040 shows remarkable antitumor activity

Colthurst terminates license agreement with Hollis-Eden for HE-2000

Weizmann reports success in developing vanadium-based antidiabetic drugs

MedImmune completes acquisition of U.S. Bioscience

Valentis initiates phase IIa trial of IFN-alpha gene medicine in angiosarcoma

Altropane phase II protocol for ADHD diagnosis submitted to FDA

Curosurf approved in U.S. for treatment of RDS in premature infants

Calcium entry blockers with potential in the treatment of prostate cancer

New Zomig formulation receives European regulatory approval

Advair approved in Canada, recommended for approval in U.S.

SB investigates CCR3 receptor blockade as a novel approach to allergic, inflammatory disorders

BASF discloses protein kinase inhibitors useful as antiangiogenic agents

New paroxetine salts as alternatives to HCl

5-HT reuptake inhibitors in development at AHP for depression and other CNS disorders

Novel antiinflammatory/analgesic designed at Chinese university

Studies presented at IDSA and in literature support LYMErix safety and efficacy in all age groups

Extensive search for HIV-1 transcription inhibitors leads to EM-2487

Fungally produced compound may be useful for delaying progression of atherosclerosis

Sawai discovers selective beta3-adrenoceptor agonist with potential as diabetes Rx

Mount Sinai investigators describe novel apoptosis-inducing agent at scientific forum

AACR-NCI-EORTC news: Japanese research team presents new hypoxic cell radiosensitizing agent

Pharmacokinetics of extended-release fampridine in MS patients discussed at AAPS meeting

IDSA highlights: IntraBiotics presents results of successful ramoplanin phase II trial

1999 AAPS: Agouron presents nasal disposition studies with AG-7088

VPA-985: PK/PD of novel aquaretic agent examined in CHF patients

Merck carbapenem performs well in complicated intraabdominal infections

Pharmacokinetics of EMD-132338 following oral administration of gantofiban

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...